FY2025 · ended Dec 31, 2025 · Revenue $32,000 · Filed Mar 11, 2026
Impact BioMedical, INC. (IBO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $32,000 and a net loss of $11.8 million.
Revenue (TTM)
$35,000
Net income (TTM)
$791,000
+102.1% vs year-ago TTM
Operating cash flow (TTM)
$-508,000
+84.9% vs year-ago TTM
Free cash flow
—
EPS
$-0.38
+83.5% vs prior year
Dividend per share
None
Shares outstanding
107.82M
+792.2% vs prior year
Net cash
—
Operating margin
-14591.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- West Henrietta, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1834105
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $32,000 | — | — |
| Operating income | -$4.3M | -$28.8M | -$4.0M |
| Net income | -$11.8M | -$24.7M | -$4.3M |
| Diluted EPS | -$0.38 | -$2.30 | -$0.07 |
| Operating cash flow | -$1.9M | -$2.9M | -$2.9M |
| Total assets | $17.4M | $20.3M | $44.6M |
| Total liabilities | $1.9M | $13.1M | $16.4M |
| Stockholders' equity | $12.6M | $4.3M | $25.2M |
| Cash and investments | $3,000 | $2.0M | $1,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 9, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 146 Impact BioMedical, INC. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.